NCT06641414Phase 3Recruiting

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06Estimated
Enrollment · participants490Estimated
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview